On Tuesday, Gilead Sciences (NASDAQ:GILD) will release its latest earnings report. Here is Benzinga's outlook for the company.

Earnings and Revenue

Based on Gilead Sciences management projections, analysts predict EPS of $1.67 on revenue of $5.73 billion.

In the same quarter last year, Gilead Sciences announced EPS of $2.70 on revenue of $7.3 billion. The Wall Street consensus estimate for earnings would represent a 38.15 percent decrease for the company. Sales would be down 21.72 percent on a year-over-year basis. Gilead Sciences's reported EPS has stacked up against analyst estimates in the past like this:

Q4 EPS Estimate: $1.67
Q4 Revenues Estimate: $5 billion

Stock Performance

Shares of Gilead Sciences were trading at $81.73. Over the last 52-week period, shares are up 13.12 percent. Given that these returns are generally positive, long-term shareholders can be content going into this earnings release.

Analyst estimates have adjusted lower for EPS and revenues over the past 90 days. The popular rating by analysts on Gilead Sciences stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Conference Call

Gilead's Q4 conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here.